Banner

Article

Linagliptin cardiovascular safety profile appears superior to glimepiride

Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.

Related Videos
© Mathematica - The Commonwealth Fund
© Mathematica - The Commonwealth Fund
© Mathematica - The Commonwealth Fund
© Mathematica - The Commonwealth Fund
Related Content
FDA approves Zepbound as first ever prescription drug to treat sleep apnea with obesity
December 20th 2024

FDA approves Zepbound as first ever prescription drug to treat sleep apnea with obesity

Jay W. Lee
December 2nd 2024

Ep 45: Vaccine hesitancy with Jay W. Lee, MD, MPH, FAAFP

© kwanchaichaiudom - stock.adobe.com
December 20th 2024

U.S. life expectancy jumped last year; FDA approves first mesenchymal stromal cell therapy to treat SR-aGVHD in pediatric patients; popular vitamins won’t prevent falls or fractures in older adults – Morning Medical Update

Ep 44: Noncompete clauses with Emma Schuering, JD
November 18th 2024

Ep 44: Noncompete clauses with Emma Schuering, JD

Dave Gilreath: ©Dave Gilreath
December 19th 2024

Great expectations may need adjusting

medical tech ai ehr: © Chinnapong - stock.adobe.com
December 19th 2024

Mastering the shift to value-based care: 3 strategies for organization-wide success